Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Capital expenditures decreased by 84% from FY24 to FY25.
Current Price
$74.81
+1.81%Arrowhead Pharmaceuticals Inc (ARWR) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Arrowhead Pharmaceuticals Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $1.09B. Gross profit (TTM) is $1.09B. EBITDA is $338.91M. Earnings per share (EPS) is $-0.01. The P/E ratio is 50.23. Market capitalization is $10.16B.
Free cash flow (FCF) is $156.89M. FCF growth rate is -0.43%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Arrowhead Pharmaceuticals Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
